Structural Requirements for Cannabinoid Receptor Probes 245Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S,
Maruani J, Neliat G, Caput D (1994) SR141716A, a potent and selective antagonist of the
brain cannabinoid receptor. FEBS Lett 350:240–244
Rinaldi-Carmona M, Barth F, Millan J, Derocq J-M, Casellas P, Congy C, Oustric D, Sarran
M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere J-C, LeFur G (1998) SR144528,
the first potent and selective antagonist for the CB2 cannabinoid receptor. J Pharmacol
Exp Ther 284:644–650
RossRA,BrockieHC,StevensonLA,MurphyVL,TempletonF,MakriyannisA,PertweeRG
(1999) Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors
of L759633, L759656, and AM630. Br J Pharmacol 126:665–672
Ryan WJ, Banner WK, Wiley JL, Martin BR, Razdan RK (1997) Potent anandamide analogs:
the effect of changing the length and branching of the end pentyl chain. J Med Chem
40:3617–3625
SchuelH,ChangMC,BurkmanLJ,PiconeRP,MakriyannisA,ZimmermanAM,Zimmerman
S (1999) Cannabinoid receptors in sperm. In: Nahas GG, Sutin KM, Agurell S (eds)
Marihuana and medicine. Humana Press, Totowa, pp 335–345
Seltzman HH, Fleming DN, Thomas BF, Gilliam AF, McCallion DS, Pertwee RG, Compton
DR, Martin BR (1997) Synthesis and pharmacological comparison of dimethylheptyl
and pentyl analogs of anandamide. J Med Chem 40:3626–3634
Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R (1997) Structural requirements for
binding of anandamide-type compounds to the brain cannabinoid receptor. J Med
Chem 40:659–667
ShimJY,Welsh WJ,Cartier E,Edwards JL,HowlettAC (2002) Molecular interaction of the an-
tagonist N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-
pyrazole-3-carboxamide with the CB1 cannabinoid receptor. J Med Chem 45:1447–1459
Shire D, Calandra B, Delpech M, Dumont X, Kaghad M, LeFur G, Caput D, Ferrar P (1996a)
Structural features of the central cannabinoid CB1 receptor involved in the binding of
the specific CB1 antagonist SR141716A. J Biol Chem 271:6941–6946
Shire D, Calandra B, Rinaldi Carmona M, Oustric D, Pessegue B, Bonnin Cabanne O, Le
Fur G, Caput D, Ferrara P (1996b) Molecular cloning, expression and function of the
murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307:132–136
Shohami E, Mechoulam R (2000) Dexanabinol (HU-211): a nonpsychotropic cannabinoid
with neuroprotective properties. Drug Dev Res 50:211–215
Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates
long-term potentiation. Nature 388:773–778
StoitAR,LangeJHM,denHartogAP,RonkenE,TipkerK,vanStuivenbergHH,Dijks-
man JAR, Wals HC, Kruse CG (2002) Design, synthesis and biological activity of rigid
cannabinoid CB1 receptor antagonists. Chem Pharm Bull (Tokyo) 50:1109–1113
Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, Takayama H, Waku K,
Seki C, Baba N, Ishima Y (1999) Evidence that the cannabinoid CB1 receptor is a 2-
arachidonoylglycerolreceptor.Structure-activityrelationshipof2-arachidonoylglycerol,
ether-linked analogues, and related compounds. J Biol Chem 274:2794–2801
Suhara Y, Takayama H, Nakane S, Miyashita T, Waku K, Sugiura T (2000) Synthesis and
biological activities of 2-arachidonoylglycerol, an endogenous cannabinoid receptor
ligand, and its metabolically stable ether-linked analogues. Chem Pharm Bull (Tokyo)
48:903–907
Tarzia G, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, Vincenzo Plazzi P, Kathuria S,
Piomelli D (2003) Synthesis and structure-activity relationships of a series of pyrrole
cannabinoid receptor agonists. Bioorg Med Chem 11:3965–3973
Thakur GA, Palmer SL, Harrington PE, Stergiades IA, Tius MA, Makriyannis A (2002) Enan-
tiomeric resolution of a novel chiral cannabinoid receptor ligand. J Biochem Biophys
Methods 54:415–422
Thomas BF, Adams IB, Mascarella SW, Martin BR, Razdan RK (1996) Structure-activity
analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J Med
Chem 39:471–479